TY - JOUR
T1 - A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer
AU - Fantini, Damiano
AU - Glaser, Alexander P.
AU - Rimar, Kalen J.
AU - Wang, Yiduo
AU - Schipma, Matthew
AU - Varghese, Nobish
AU - Rademaker, Alfred
AU - Behdad, Amir
AU - Yellapa, Aparna
AU - Yu, Yanni
AU - Sze, Christie Ching Lin
AU - Wang, Lu
AU - Zhao, Zibo
AU - Crawford, Susan E.
AU - Hu, Deqing
AU - Licht, Jonathan D.
AU - Collings, Clayton K.
AU - Bartom, Elizabeth
AU - Theodorescu, Dan
AU - Shilatifard, Ali
AU - Meeks, Joshua J.
N1 - Funding Information:
Acknowledgements The authors thank Dr. Francesco Favero (Technical University of Denmark) for assistance with the use of the sequenza and copynumber R libraries, Dr. Vania Vidimar (North-western University) for insightful discussions and editorial assistance in writing the manuscript, and Dr. Andrea Piunti (Northwestern University) for help with RNA extraction and RNA-seq library preparation. JJM is supported by grant BX003692 and the John P. Hanson Foundation for Cancer Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, JDL is supported by R01 CA180475, DT is supported by CA075115. CKC, EB and AS are supported by R35CA197569 awarded to AS.
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/4/1
Y1 - 2018/4/1
N2 - The N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) mouse model is an attractive model system of muscle-invasive bladder cancer (MIBC) as it recapitulates the histology of human tumors in a background with intact immune system. However, it was unknown whether this carcinogen-induced model also mimicked human MIBC at the molecular and mutational level. In our study, we analyzed gene expression and mutational landscape of the BBN model by next-generation sequencing followed by a bioinformatic comparison to human MIBC using data from The Cancer Genome Atlas and other repositories. BBN tumors showed overexpression of markers of basal cancer subtype, and had a high mutation burden with frequent Trp53 (80%), Kmt2d (70%), and Kmt2c (90%) mutations by exome sequencing, similar to human MIBC. Many variants corresponded to human cancer hotspot mutations, supporting their role as driver mutations. We extracted two novel mutational signatures from the BBN mouse genomes. The integrated analysis of mutation frequencies and signatures highlighted the contribution of aberrations to chromatin regulators and genetic instability in the BBN tumors. Together, our study revealed several similarities between human MIBC and the BBN mouse model, providing a strong rationale for its use in molecular and drug discovery studies.
AB - The N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) mouse model is an attractive model system of muscle-invasive bladder cancer (MIBC) as it recapitulates the histology of human tumors in a background with intact immune system. However, it was unknown whether this carcinogen-induced model also mimicked human MIBC at the molecular and mutational level. In our study, we analyzed gene expression and mutational landscape of the BBN model by next-generation sequencing followed by a bioinformatic comparison to human MIBC using data from The Cancer Genome Atlas and other repositories. BBN tumors showed overexpression of markers of basal cancer subtype, and had a high mutation burden with frequent Trp53 (80%), Kmt2d (70%), and Kmt2c (90%) mutations by exome sequencing, similar to human MIBC. Many variants corresponded to human cancer hotspot mutations, supporting their role as driver mutations. We extracted two novel mutational signatures from the BBN mouse genomes. The integrated analysis of mutation frequencies and signatures highlighted the contribution of aberrations to chromatin regulators and genetic instability in the BBN tumors. Together, our study revealed several similarities between human MIBC and the BBN mouse model, providing a strong rationale for its use in molecular and drug discovery studies.
UR - http://www.scopus.com/inward/record.url?scp=85040924638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040924638&partnerID=8YFLogxK
U2 - 10.1038/s41388-017-0099-6
DO - 10.1038/s41388-017-0099-6
M3 - Article
C2 - 29367767
AN - SCOPUS:85040924638
SN - 0950-9232
VL - 37
SP - 1911
EP - 1925
JO - Oncogene
JF - Oncogene
IS - 14
ER -